A Phase 1, Pharmacokinetically-Guided, Dose Escalation Study to Assess the Safety and Tolerability of Dexanabinol in Patients With Advanced Solid Tumours.

Trial Profile

A Phase 1, Pharmacokinetically-Guided, Dose Escalation Study to Assess the Safety and Tolerability of Dexanabinol in Patients With Advanced Solid Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2017

At a glance

  • Drugs Dexanabinol (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors e-Therapeutics
  • Most Recent Events

    • 03 Aug 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 08 Jun 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jul 2015, as reported by ClinicalTrials.gov.
    • 08 Jun 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top